Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Michael is the Executive Vice President, Head of Research and Development at Repare Therapeutics. Prior to joining Repare, he led the oncology bioscience organization at AstraZeneca R&D Boston. In this role he served on the global science leadership team, oncology research board and the Acerta research and early development teams accountable for strategy, key collaborations/partnerships and delivery of an innovative portfolio of patient centric drug discovery programs.
He helped to transform the AstraZeneca pipeline through strategic builds in the immuno-oncology, tumor drivers and resistance and DNA damage response areas. His group delivered multiple novel therapies in the clinic including inhibitors of protein-protein interactions, enzymatic function, bromodomain interactions and nucleic acid based therapeutics in collaboration with Ionis Pharmaceuticals.
Dr. Michael Zinda holds a B.Sc. In Biology from the Minnesota State University Moorhead and a Ph.D. In Molecular Biology from Vanderbilt University. He received his post-doctoral training at Princeton University and Eli Lilly & Company.